Friday 30 January 2015

FDA expands use of Imbruvica to treat rare form of blood cancer

The U.S. Food and Drug Administration approved the expanded use of Imbruvica, sold by Johnson & Johnson and Pharmacyclics Inc, to treat Waldenström's macroglobulinemia (WM), a rare form of blood cancer for which no specific pharmaceutical therapy exists. WM, a type of non-Hodgkin lymphoma, was discovered more than 70 years ago. It usually worsens slowly over time and causes abnormal blood cells, known as B lymphocytes (B-cells), to grow within the bone marrow, lymph nodes, liver and spleen. The FDA granted Imbruvica breakthrough therapy designation for WM, a status given to drugs seen as important advances in the treatment of serious diseases, but it added a warning that it could cause tumor lysis syndrome (TLS). via Health News Headlines - Yahoo News Read More Here..


Lake forest health and fitness http://ift.tt/1ByuFUH

1 comment:

  1. this article is very useful for me to know about Imbruvica 140mg capsules | Ibrutinib | Apple pharmaceuticals details...,
    thank you for sharing this article..,
    Imbruvica 140mg,Imbruvica 140mg capsules

    ReplyDelete